Thus, it is plausible that 2–3 years before the diagnosis of cancer, PCA3-shRNA2 expression is not elevated, as the target mRNAs (such as COPS2 and SOX11) do not have, as yet, altered function in the prostate. Here, PCA3 is linked to cancer.